Treatment of periocular XXXX with @entity1169 : case series of 18 @entity1 .

@entity1169 @entity1 @entity940 @entity11126 @entity7492 @entity735 @entity551 @entity4457
PURPOSE: To study the efficacy of @entity1169 in the treatment of periocular @entity7492 ( @entity7492 ). DESIGN: Retrospective interventional case series. @entity1 : Eighteen @entity1 presenting periocular @entity11126 with occlusion of the pupil, anisometropic @entity940 , proliferating eyelid @entity11126 , or cosmetically disfiguring periocular @entity11126 . METHODS: All @entity1 received treatment with @entity1169 started at 0.5 mg/kg/day with an incremental increase by 0.5 mg/kg/day every 4 days, up to a maximum of 2 to 3 mg/kg/day. @entity735 and serial photographs were obtained before, during, and after treatment. Doppler ultrasound and magnetic resonance imaging performed pre- and post-treatment were compared when available. MAIN OUTCOME MEASURES: Evolution of the treated @entity11126 was evaluated with respect to @entity940 , @entity4457 , and size of the lesion. RESULTS: The @entity11126 size decreased in 17 of 18 @entity1 . We noted a greater reduction when treatment was administered during the proliferative phase of growth of @entity7492 . At the conclusion of treatment, none of our @entity1 had @entity4457 . The mean value of amblyogenic @entity940 (n = 7) decreased from 2.71 diopters (D) pretreatment to 1.03 D post-treatment. On radiology, 8 @entity1 had significant regression of the lesion size of their @entity11126 and 1 @entity1 had a limited progression. @entity1169 had to be temporarily discontinued in only 1 @entity1 because of symptomatic @entity551 . CONCLUSIONS: @entity1169 seems to be an effective modality of treatment for periocular @entity11126 . It seems to be most efficacious when initiated in the proliferative phase of @entity11126 but may be beneficial even in the later stage. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
